Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 9/20 | 0.48 |
| ▸ | CES1 | P23141 | 8/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715587 | 0.93 | CES2 (0.52) | CES2CES1SSTR4HDAC3HDAC1 | |
| SCHEMBL2712662 | 0.86 | SSTR4 (0.53) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2035077 | 0.83 | RAB9A (0.35) | CES2CES1SSTR4HDAC3HDAC1 | |
| SCHEMBL2035076 | 0.83 | RAB9A (0.35) | CES2CES1SSTR4HDAC3HDAC1 | |
| SCHEMBL3560390 | 0.83 | SSTR4 (0.56) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2699856 | 0.82 | MAPT (0.40) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL6620132 | 0.81 | SSTR4 (0.59) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4734872 | 0.81 | MAPT (0.49) | SSTR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL12133598 | 0.81 | AKT1 (0.45) | CES2CES1SSTR4HDAC3HDAC1 | |
| SCHEMBL13254923 | 0.79 | SSTR4 (0.42) | SSTR4HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104669-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8288407-B2 | Substituted naphthyridine compounds as inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| EP-2104669-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2009-09-30 | — | — | EP | disclosed |
| US-7576209-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080161317-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
| WO-2008070016-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161317-A1 | Inhibitors of Akt activity | PIK3CD, PIK3CA, PIK3CG | CES2 3656/4885CES1 2286/4885SSTR4 3864/4885 |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | CES2 3656/4885CES1 2286/4885SSTR4 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.